AG
AUTL

Advisor Group’s Autolus Therapeutics AUTL Stock Holding History

Advisor Group’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$9K Buy
+700
New +$9.16K ﹤0.01% 4407

Other funds holding AUTL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Advisor Group's AUTL Position: Q4 2019 in Review

Advisor Group opened a new position in Autolus Therapeutics (AUTL) in Q4 2019: 700 shares worth $9K. The stake represents ﹤0.01% of the portfolio and ranks #4407 among its holdings.

55 funds tracked by Wall St. Rank hold AUTL as of Q4 2019.

  • Advisor Group held 700 shares of Autolus Therapeutics worth $9K as of Q4 2019.
  • Autolus Therapeutics was a new Advisor Group position in Q4 2019.
  • Autolus Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4407 holding.
  • 55 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.